Title:
ANTIBODY-DRUG CONJUGATE INCLUDING ANTIBODY AGAINST HUMAN CLDN18.2, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/211508
Kind Code:
A1
Abstract:
The present invention relates to: a novel antibody-drug conjugate (ADC) targeting claudin 18 isoform 2 (CLDN18.2); an active metabolite of the ADC; a method for producing the ADC; a use of the ADC for treating and/or preventing diseases; and a use of the ADC for producing medicaments for treating and/or preventing diseases, more specifically, hyperproliferative and/or angiogenic diseases, for example, cancer. More particularly, the present invention relates to an antibody-drug conjugate comprising an antibody binding to CLDN18.2 or an antigen-binding fragment thereof, and to a pharmaceutical composition comprising same.
Inventors:
PARK CHANG SIK (KR)
SONG HO YOUNG (KR)
JANG TAE IK (KR)
CHUNG CHUL-WOONG (KR)
JHENG MING-JIN (CN)
SONG HO YOUNG (KR)
JANG TAE IK (KR)
CHUNG CHUL-WOONG (KR)
JHENG MING-JIN (CN)
Application Number:
PCT/KR2022/004552
Publication Date:
October 06, 2022
Filing Date:
March 30, 2022
Export Citation:
Assignee:
LEGOCHEM BIOSCIENCES INC (KR)
HARBOUR BIOMED SUZHOU CO LTD (CN)
HARBOUR BIOMED SUZHOU CO LTD (CN)
International Classes:
A61K47/68; A61K31/5517; A61K38/05; A61K45/06; A61K47/65; A61P35/00
Domestic Patent References:
| WO2019242505A1 | 2019-12-26 | |||
| WO2017089895A1 | 2017-06-01 | |||
| WO2017089890A1 | 2017-06-01 |
Foreign References:
| KR20180079452A | 2018-07-10 | |||
| KR20180110649A | 2018-10-10 | |||
| KR101628872B1 | 2016-06-09 | |||
| US6214345B1 | 2001-04-10 | |||
| US5122368A | 1992-06-16 | |||
| US5824805A | 1998-10-20 | |||
| US5622929A | 1997-04-22 | |||
| US4880935A | 1989-11-14 | |||
| CN2020118650W | 2020-09-29 | |||
| KR20180110645A | 2018-10-10 | |||
| KR20140035393A | 2014-03-21 |
Other References:
GUOYUN ZHU, FOLETTI DAVIDE, LIU XIAOHUI, DING SHENG, MELTON WITT JODY, HASA-MORENO ADELA, RICKERT MATHIAS, HOLZ CHARLES, ASCHENBRE: "Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer", SCIENTIFIC REPORTS, vol. 9, no. 1, 1 January 2019 (2019-01-01), pages 1 - 11, XP055630964, DOI: 10.1038/s41598-019-44874-0
JOONG-JAE LEE, HYO-JUNG CHOI, MISUN YUN, YINGJIN KANG, JI-EUN JUNG, YISEUL RYU, TAE YOON KIM, YOUNG-JE CHA, HYUN-SOO CHO, JUNG-JOO: "Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein-Drug Conjugates for Targeted Therapy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, vol. 54, no. 41, 5 October 2015 (2015-10-05), pages 12020 - 12024, XP055385290, ISSN: 1433-7851, DOI: 10.1002/anie.201505964
DISCOVERY MEDICINE, vol. 10, no. 53, 2010, pages 329 - 39
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
NEVILLE ET AL., BIOL. CHEM., vol. 264, 1989, pages 14653 - 14661
THORPE ET AL., CANCER RES, vol. 47, 1987, pages 5924 - 5931
JOHNSON ET AL., ANTICANCER RES, vol. 15, 1995, pages 1387 - 93
LAU ET AL., BIOORG-MED-CHEM., vol. 3, no. 10, 1995, pages 1305 - 1304
JEFFERY ET AL., BIOCONJUG CHEM., vol. 17, no. 3, 2006, pages 832 - 40
KOLODYCH ET AL., EUR J MED CHEM., vol. 142, 15 December 2017 (2017-12-15), pages 376 - 382
DUNCAN, A. R.J. M. WOOFL. J. PARTRIDGED. R. BURTONG. WINTER: "Localisation of the binding site for the human high-affinity Fc receptoron IgG", NATURE, vol. 332, 1988, pages 563 - 564
LUND, J.G. WINTERP. T. JONESJ. D. POUNDT. TANAKAM. R. WALKERP. J. ARTYMIUKY. ARATAD. R. BURTONR. JEFFERIS: "Human FcγRl and FcγRll interact with distinct but overlapping sites on human IgG", J. IMMUNOL., vol. 147, 1991, pages 2657 - 2662
SARMAY, G.J. LUNDZ. ROZSNAYAYJ. GERGELEYR. JEFFERIS: "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc receptor", MOL. IMMUNOL., vol. 29, 1992, pages 633 - 639, XP023683016, DOI: 10.1016/0161-5890(92)90200-H
JOONG-JAE LEE, HYO-JUNG CHOI, MISUN YUN, YINGJIN KANG, JI-EUN JUNG, YISEUL RYU, TAE YOON KIM, YOUNG-JE CHA, HYUN-SOO CHO, JUNG-JOO: "Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein-Drug Conjugates for Targeted Therapy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, vol. 54, no. 41, 5 October 2015 (2015-10-05), pages 12020 - 12024, XP055385290, ISSN: 1433-7851, DOI: 10.1002/anie.201505964
DISCOVERY MEDICINE, vol. 10, no. 53, 2010, pages 329 - 39
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123
NEVILLE ET AL., BIOL. CHEM., vol. 264, 1989, pages 14653 - 14661
THORPE ET AL., CANCER RES, vol. 47, 1987, pages 5924 - 5931
JOHNSON ET AL., ANTICANCER RES, vol. 15, 1995, pages 1387 - 93
LAU ET AL., BIOORG-MED-CHEM., vol. 3, no. 10, 1995, pages 1305 - 1304
JEFFERY ET AL., BIOCONJUG CHEM., vol. 17, no. 3, 2006, pages 832 - 40
KOLODYCH ET AL., EUR J MED CHEM., vol. 142, 15 December 2017 (2017-12-15), pages 376 - 382
DUNCAN, A. R.J. M. WOOFL. J. PARTRIDGED. R. BURTONG. WINTER: "Localisation of the binding site for the human high-affinity Fc receptoron IgG", NATURE, vol. 332, 1988, pages 563 - 564
LUND, J.G. WINTERP. T. JONESJ. D. POUNDT. TANAKAM. R. WALKERP. J. ARTYMIUKY. ARATAD. R. BURTONR. JEFFERIS: "Human FcγRl and FcγRll interact with distinct but overlapping sites on human IgG", J. IMMUNOL., vol. 147, 1991, pages 2657 - 2662
SARMAY, G.J. LUNDZ. ROZSNAYAYJ. GERGELEYR. JEFFERIS: "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc receptor", MOL. IMMUNOL., vol. 29, 1992, pages 633 - 639, XP023683016, DOI: 10.1016/0161-5890(92)90200-H
Attorney, Agent or Firm:
HANSUNG INTELLECTUAL PROPERTY (KR)
Download PDF: